AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00336973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efalizumab
Description: Subcutaneous repeating dose
Study NCT02114437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop TCI
Description: the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
Study NCT02114437 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Opened-loop TCI
Description: the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
Study NCT03594227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATI-501 400mg BID (Low dose)
Description: ATI-501 400mg BID oral low dose for oral administration
Study NCT03594227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATI-501 600mg BID (Mid dose)
Description: ATI-501 600mg BID oral mid dose for oral administration
Study NCT01138449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: Retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil, orally as a single dose to neonates on the day of birth or in the next 2 days of birth keeping a minimum period of 2 hours between the birth and the dosing
Study NCT01138449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil, orally as a single dose to neonates on the day of birth or in the next 2 days of birth keeping a minimum period of 2 hours between the birth and the dosing
Study NCT01539161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardiac Monitor
Description: 9529 Reveal XT Implantable Cardiac Monitor as well as the use of 9539 Reveal XT Patient Assistant.
Study NCT01539161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care arm including exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months.
Study NCT01276210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO
Study NCT01276210 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo stereotactic radiosurgery
Study NCT01276210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00281242 — intervention group
Intervention type: OTHER
Intervention: blood draw
Description: All subjects undergo blood draws at study visits and at the time of COPD exacerbation visits.
Study NCT02239419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2-Enriched Tap Water (Carbothera)
Description: Participants will undergo foot bathing with CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
Study NCT02239419 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-CO2-Enriched Tap Water
Description: Participants will undergo foot bathing with non-CO2-enriched tap water maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
Study NCT03525795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-1205
Description: Administered orally
Study NCT03525795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Administered intravenously
Study NCT01088867 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Acupuncture
Description: Electroacupuncture
Study NCT03394820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The intervention is the time when dexamethasone is administered
Study NCT03394820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The intervention is the time when dexamethasone is administered
Study NCT01712477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous sedation using propofol
Description: Patients will be given intravenous sedation for treatment of traumatic brain injury requiring mechanical ventilation
Study NCT01712477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous sedation with midazolam
Description: patients with severe traumatic brain injury requiring mechanical ventilation and sedation will be sedated with midazolam
Study NCT01017198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB021 and Food
Description: Assessing the effect of food use on BIIB021
Study NCT01017198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB0121 and Antacid
Description: Assessing the effect of antacid use on BIIB021
Study NCT03594227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATI-501 800mg BID (High dose)
Description: ATI-501 800mg BID high dose for oral administration
Study NCT03594227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - oral administration
Study NCT00769184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: One side of body:~clobetasol: 2 applications / day along with LCD application 2 applications/day
Study NCT00769184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid
Description: One side of body:~clobetasol: 2 applications / day along with LCD application 2 applications/day
Study NCT00769184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One side of body:~Placebo Solution: 2 applications / day along with clobetasol 2 applications/day
Study NCT00769184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCD
Description: One side of body:~LCD Solution: 2 applications / day along with clobetasol 2 applications/day
Study NCT02568813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiscore Depression Inventory for Children scale
Study NCT02791061 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imagine (MRI)
Description: MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images.
Study NCT02791061 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary exercise testing (CPET)
Description: Cardiopulmonary exercise testing (CPET) is non-invasive simultaneous measurement of the cardiovascular and respiratory system during exercise to assess a patient's exercise capacity.
Study NCT02791061 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
Study NCT02682628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study NCT00135668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroprusside
Description: Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS (Interactive Voice Response System).
Study NCT00135668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroprusside
Description: Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS.
Study NCT00135668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroprusside
Description: Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS
Study NCT04863300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative stepped care and peer support
Description: Case identification will be done through open referral and outreach activities such as street booth, talks, and home visits.~For older adults with mild depressive symptoms (PHQ-9 score 5-9), 6-8 weeks of indicated prevention with psychoeducation or low-intensity psychotherapy would be provided by the project social workers in DECC. For participants with moderate depressive symptoms (PHQ-9 score 10-14), 6-8 weeks high-intensity clinical intervention, mainly group cognitive behavioral therapy (CBT), would be provided by project social workers from DECC and ICCMW. For those with moderately severe depressive symptoms (PHQ-9 score 15-19), 8-10 weeks individual CBT or group CBT at higher frequency would be provided by the project social workers from ICCMW.~In the progress review when a client is assessed to meet the discharge criteria, a 2-month exit plan involving a Peer Supporter follow-up is invoked.
Study NCT02267694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Freeze-dried black raspberry powder
Study NCT02688595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound-guided central venous catheterization in internal jugular vein
Study NCT02688595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Scheduled operation under general anesthesia
Study NCT00884273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
Study NCT00884273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.
Study NCT00884273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin.
Study NCT02586935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tideglusib
Description: Administered orally after dispersion in approximately 100 ml of water at dose levels of 400 to 1000 mg
Study NCT02586935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally after dispersion in approximately 100 ml of water
Study NCT02982135 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: bypass surgery and indrect bypass surgery
Description: bypass surgery ： patients recieved STA-MCA bypass indrect bypass surgery：patients recieved EDAS or mutiple bur holes
Study NCT04788121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS
Study NCT04788121 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: For management, initial priority will be given to secure airway, breathing and circulation. To ensure hemodynamic stability, crystalloids infusion will be given as and when required. Blood transfusion will be initiated at the threshold hemoglobin (Hb) of 7g/dl, to maintain the target Hb of 7-9g/dl or with signs of hemodynamic instability despite fluid resuscitation. Intra venous (IV) PPI and antibiotic will be started promptly in all cases and IV splanchnic vasoconstrictor will be given in all suspicious case of Variceal hemorrhage before definitive therapeutic and diagnostic endoscopic procedure is done.
Study NCT04788121 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: For management, initial priority will be given to secure airway, breathing and circulation. To ensure hemodynamic stability, crystalloids infusion will be given as and when required. Blood transfusion will be initiated at the threshold hemoglobin (Hb) of 7g/dl, to maintain the target Hb of 7-9g/dl or with signs of hemodynamic instability despite fluid resuscitation. Intra venous (IV) PPI and antibiotic will be started promptly in all cases and IV splanchnic vasoconstrictor will be given in all suspicious case of Variceal hemorrhage before definitive therapeutic and diagnostic endoscopic procedure is done.
Study NCT00725400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab and Radiation Therapy
Description: Patients will receive Cetuximab and Radiation Therapy. Patients will receive a dose of Cetuximab through Intravenous (IV). The initial dose is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min) and weekly dose is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
Study NCT00725400 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery and Radiation Therapy
Description: Patients will undergo Surgery before or after Radiation Therapy. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
Study NCT02055105 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: miRNA in Sepsis
Description: miRNA in Sepsis
Study NCT03953066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The calculation of blood IL-6 and coloctral milk melatonin
Description: Collected maternal colostral milk will be sampled for melatonin levels.Blood samples driven before and after delivery will be evaluated for IL-6 levels in each group
Study NCT02752516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Study NCT03045562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients will be assigned to receive 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
Study NCT03045562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvianolate injection
Description: Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
Study NCT00623428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Study NCT00623428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a
Study NCT00623428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT00623428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study NCT00641498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Individual supportive
Study NCT04599283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MenHealth Uroflowmeter
Description: MenHealth Uroflowmeter is a mobile application and FDA cleared medical device that analyzes the sound of urine hitting the toilet water when a male urinates and generates voiding data (maximum flow, average flow, and voided volume) and a flow curve. All test results are saved in an automated voiding diary.
Study NCT02702765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibroscan
Description: Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure
Study NCT02702765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound is a non-invasive procedure
Study NCT02702765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galactose
Description: Galactose elimination capacity is performed to evaluate metabolic liver function.~The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours.
Study NCT02702765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver biopsy
Description: Histological disease activity at time of diagnosis evaluating if any liver fibrosis
Study NCT02702765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional hepatic nitrogen clearance
Description: Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearance requires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours
Study NCT03999762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sample prep
Description: Effectiveness of a sample preparation protocol
Study NCT03999762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sample prep
Description: Effectiveness of a sample preparation protocol
Study NCT03792815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: busulfan 3.2mg/kg iv on day -8, -7, and -6,
Study NCT03792815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: melphalan 50mg/m2/day i.v. on day -3 and -2
Study NCT03792815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: etoposide 400 mg/m2 i.v. on day -5 and -4
Study NCT03223545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-T
Description: This 8-week program combines mindfulness training with cognitive therapy and is delivered to small groups of patients by telephone using a conference line. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home-based practice assignment.
Study NCT03223545 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Treatment guidelines recommend counseling patients with prehypertension on the importance of lifestyle modification to reduce BP. Because of variability in counseling across primary care practices, the study team will provide all participants with NHLBI print educational materials to ensure exposure to lifestyle recommendations: Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan.
Study NCT01367535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Methylnaltrexone (MNTX)
Study NCT01367535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Methylnaltrexone (MNTX)
Study NCT01367535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Paroxetine
Study NCT01367535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SC Placebo
Study NCT02039375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hopkins post tPA for ischemic stroke monitoring protocol
Description: The Hopkins post tPA monitoring protocol includes: vital signs and neurochecks, per standard of care for the first two hours (every 15 minutes), then on arrival to unit, in one hour, every 2 hours for 8 hours, and every 4 hours to complete 24 hours.
Study NCT01102647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phytosterol ester
Description: 1.6 g phytosterols/day for 29 days
Study NCT01356082 — intervention group
Intervention type: DEVICE
Intervention: CNAP
Description: Non-invasive blood pressure monitor
Study NCT03278470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL237
Description: Experimental
Study NCT03278470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: placebo with same properties except for active ingredient